Icagen Inc Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 5 Calls Today's Calls

Call Details Icagen Inc Earnings Conference Call (Q3 2009) Thu, Nov 5, 2009, 10:00 am Eastern Listen to the archived event audio About Icagen Inc (NasdaqGM:ICGN) Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company’s primary drug candidates include ICA-105665 that is in the Phase I multiple ascending dose study in healthy volunteers and epilepsy patients for epilepsy and neuropathic pain; and Senicapoc, which is in the Phase II proof-of-concept clinical trials for the treatment of asthma. It also engages in conducting ongoing drug discovery programs that focus on new therapeutics for pain and inflammatory disorders. Icagen, Inc. has a collaborative research and license agreement with Pfizer Inc. for the discovery, development, manufacture, and commercialization of compounds and products that modulate three specific sodium ion channels as new potential treatments for pain and related disorders. The company was founded in 1992 and is based in Durham, North Carolina. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials